Draft Guidances For 2013 Will Grapple With Biosimilars, Track and Trace, Compounding
Executive Summary
FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.
You may also be interested in...
FDA Plans Five Biosimilar, Three Social Media Draft Guidances In 2014
Additional draft guidances address implementation of the Drug Supply Chain Security Act, multiple endpoints in clinical trials, and public disclosure of FDA-sponsored studies.
FDA Antimicrobial Development Draft Guidances Withdrawn Under Rejuvenation Initiative
FDA says the 13 guidances are out of date and of no use to industry; a number of others covering various topics also will be revised or finalized.
Clinical Trial Dropouts, Missing Data Get FDA Attention At GSK Anoro Ellipta Review
More than a year after hints of forthcoming guidance on missing data, agency looks toward future where sponsors do more to retain patients and follow up on those that leave clinical trials.